These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
157 related items for PubMed ID: 11598161
1. Correlation of nuclear morphometry with pathologic parameters in ductal carcinoma in situ of the breast. Tan PH, Goh BB, Chiang G, Bay BH. Mod Pathol; 2001 Oct; 14(10):937-41. PubMed ID: 11598161 [Abstract] [Full Text] [Related]
2. Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast. Hoque A, Lippman SM, Boiko IV, Atkinson EN, Sneige N, Sahin A, Weber DM, Risin S, Lagios MD, Schwarting R, Colburn WJ, Dhingra K, Follen M, Kelloff GJ, Boone CW, Hittelman WN. Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):249-59. PubMed ID: 11303595 [Abstract] [Full Text] [Related]
3. Quantitative study of breast cancer progression: different pathways for various in situ cancers. Mariuzzi L, Mombello A, Granchelli G, Rucco V, Tarocco E, Frank D, Davis J, Thompson D, Bartels H, Mariuzzi GM, Bartels PH. Mod Pathol; 2002 Jan; 15(1):18-25. PubMed ID: 11796837 [Abstract] [Full Text] [Related]
4. Breast carcinoma in women 35 years and younger: a pathological study. Fernandopulle SM, Cher-Siangang P, Tan PH. Pathology; 2006 Jun; 38(3):219-22. PubMed ID: 16753742 [Abstract] [Full Text] [Related]
5. Pure ductal carcinoma in situ and in situ component of ductal invasive carcinoma of the breast. A preliminary morphometric study. Giardina C, Serio G, Lepore G, Lettini T, Dalena AM, Pennella A, D'Eredità G, Valente T, Ricco R. J Exp Clin Cancer Res; 2003 Jun; 22(2):279-88. PubMed ID: 12866579 [Abstract] [Full Text] [Related]
6. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. Ottesen GL. APMIS Suppl; 2003 Jun; (108):1-67. PubMed ID: 12874968 [Abstract] [Full Text] [Related]
12. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Hoque A, Sneige N, Sahin AA, Menter DG, Bacus JW, Hortobagyi GN, Lippman SM. Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):587-90. PubMed ID: 12050101 [Abstract] [Full Text] [Related]
17. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study. Altintas S, Lambein K, Huizing MT, Braems G, Asjoe FT, Hellemans H, Van Marck E, Weyler J, Praet M, Van den Broecke R, Vermorken JB, Tjalma WA. Breast J; 2009 Jun; 15(2):120-32. PubMed ID: 19292797 [Abstract] [Full Text] [Related]
18. American Society of Breast Surgeons MammoSite Radiation Therapy System Registry Trial: ductal carcinoma-in-situ subset analysis--4-year data in 194 treated lesions. Keisch M, Vicini F, Beitsch P, Quiet C, Keleher A, Garcia D, Snider H, Gittleman M, Zannis V, Kuerer H. Am J Surg; 2009 Oct; 198(4):505-7. PubMed ID: 19800456 [Abstract] [Full Text] [Related]
19. Defining negative margins in DCIS patients treated with breast conservation therapy: The University of Chicago experience. Sahoo S, Recant WM, Jaskowiak N, Tong L, Heimann R. Breast J; 2005 Oct; 11(4):242-7. PubMed ID: 15982389 [Abstract] [Full Text] [Related]